Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term extension of carbetocin nasal spray for hyperphagia in Prader-Willi syndrome
2023-506201-19-00Phase 3Completed
- Sponsor
- Acadia Pharmaceuticals
- Start
- Mar 2025
- Modality
- Peptides
- Countries
- 5
01
Overview
Phase 3, open-label, single-arm trial of carbetocin in Prader-Willi syndrome (PWS), sponsored by Acadia Pharmaceuticals. Primary endpoints: Treatment-emergent adverse events, Serious adverse events and 3 more. Started Mar 2025; status: completed.
02
Drugs
carbetocin
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on 2023-506201-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506201-19-00.